DE2824165C2 - Verwendung von β-(p-Halogenphenyl)-γ-aminobuttersäure - Google Patents
Verwendung von β-(p-Halogenphenyl)-γ-aminobuttersäureInfo
- Publication number
- DE2824165C2 DE2824165C2 DE2824165A DE2824165A DE2824165C2 DE 2824165 C2 DE2824165 C2 DE 2824165C2 DE 2824165 A DE2824165 A DE 2824165A DE 2824165 A DE2824165 A DE 2824165A DE 2824165 C2 DE2824165 C2 DE 2824165C2
- Authority
- DE
- Germany
- Prior art keywords
- udf54
- udf53
- aminobutyric acid
- halophenyl
- anxiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229960003692 gamma aminobutyric acid Drugs 0.000 title claims description 5
- 208000019901 Anxiety disease Diseases 0.000 claims description 13
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000007848 Alcoholism Diseases 0.000 description 2
- 206010001584 alcohol abuse Diseases 0.000 description 2
- 208000025746 alcohol use disease Diseases 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 229940005530 anxiolytics Drugs 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- QWHXHLDNSXLAPX-UHFFFAOYSA-N 4-amino-3-(4-fluorophenyl)butanoic acid Chemical compound OC(=O)CC(CN)C1=CC=C(F)C=C1 QWHXHLDNSXLAPX-UHFFFAOYSA-N 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010008531 Chills Diseases 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010066392 Fear of death Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutanoic acid Natural products NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- -1 β- (p-bromophenyl) -γ- aminobutyric acid Chemical compound 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL7706429A NL7706429A (nl) | 1977-06-10 | 1977-06-10 | Werkwijze voor de bereiding van een geneesmid- del met angst en angstequivalenten opheffende werking en gevormd geneesmiddel met een derge- lijke werking. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2824165A1 DE2824165A1 (de) | 1978-12-21 |
| DE2824165C2 true DE2824165C2 (de) | 1987-04-30 |
Family
ID=19828697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2824165A Expired DE2824165C2 (de) | 1977-06-10 | 1978-06-02 | Verwendung von β-(p-Halogenphenyl)-γ-aminobuttersäure |
Country Status (8)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4368206A (en) * | 1974-03-11 | 1983-01-11 | Emanuel Revici | Method for treating alcoholism and eliminating and preventing alcohol intoxication |
| NL8006135A (nl) * | 1980-11-10 | 1982-06-01 | Univ Erasmus | Geneesmiddel met angst en angstequivalenten opheffende werking en werkwijze voor de bereiding van een dergelijk geneesmiddel. |
| PH26730A (en) * | 1988-12-30 | 1992-09-28 | Ciba Geigy Ag | Coated adhesive tablets |
| US4973467A (en) * | 1989-10-13 | 1990-11-27 | Natrol, Inc. | Dietary supplement for adults |
| US4980168A (en) * | 1989-10-13 | 1990-12-25 | Natrol, Inc. | Dietary supplement for children |
| US5050667A (en) * | 1990-05-15 | 1991-09-24 | Erling Berner | Air ventilation and heat exchange apparatus |
| FR2662354B1 (fr) * | 1990-05-23 | 1994-10-07 | Adir | Utilisation du baclofene pour l'obtention de medicaments destines au traitement de l'angine de poitrine. |
| US6770468B1 (en) | 1999-09-14 | 2004-08-03 | Genzyme Glycobiology Research Institute, Inc. | Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway |
| US6642038B1 (en) | 1999-09-14 | 2003-11-04 | Genzyme Glycobiology Research Institute, Inc. | GlcNAc phosphotransferase of the lysosomal targeting pathway |
| US6800472B2 (en) * | 2001-12-21 | 2004-10-05 | Genzyme Glycobiology Research Institute, Inc. | Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase |
| US6905856B2 (en) | 2001-12-21 | 2005-06-14 | Genzyme Glycobiology Research Institute, Inc. | Soluble GlcNAc phosphotransferase |
| US20030124652A1 (en) * | 2001-12-21 | 2003-07-03 | Novazyme Pharmaceuticals, Inc. | Methods of producing high mannose glycoproteins in complex carbohydrate deficient cells |
| PT1660440E (pt) * | 2003-08-20 | 2012-05-15 | Xenoport Inc | Pró-fármacos de aciloxialquilcarbamato, métodos de síntese e utilização |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH449645A (de) * | 1963-07-09 | 1968-01-15 | Ciba Geigy | Verfahren zur Herstellung neuer Aminosäuren |
| US3947579A (en) * | 1974-06-03 | 1976-03-30 | Nelson Research & Development Company | Method and composition for potentiating neuroleptic drugs |
-
1977
- 1977-06-10 NL NL7706429A patent/NL7706429A/xx unknown
-
1978
- 1978-05-29 BE BE181131A patent/BE867588A/xx not_active IP Right Cessation
- 1978-06-02 SE SE7806494A patent/SE7806494L/xx unknown
- 1978-06-02 DE DE2824165A patent/DE2824165C2/de not_active Expired
- 1978-06-09 FR FR787817322A patent/FR2393577A1/fr active Granted
- 1978-06-09 IT IT68351/78A patent/IT1107805B/it active
- 1978-06-09 US US05/914,087 patent/US4156013A/en not_active Expired - Lifetime
- 1978-06-12 GB GB7826688A patent/GB2000027A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| NL7706429A (nl) | 1978-12-12 |
| FR2393577A1 (fr) | 1979-01-05 |
| IT7868351A0 (it) | 1978-06-09 |
| BE867588A (nl) | 1978-09-18 |
| IT1107805B (it) | 1985-12-02 |
| GB2000027A (en) | 1979-01-04 |
| DE2824165A1 (de) | 1978-12-21 |
| US4156013A (en) | 1979-05-22 |
| FR2393577B1 (US08188275-20120529-C00054.png) | 1981-11-20 |
| SE7806494L (sv) | 1978-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2824165C2 (de) | Verwendung von β-(p-Halogenphenyl)-γ-aminobuttersäure | |
| DE2920739C2 (US08188275-20120529-C00054.png) | ||
| DE2856393C2 (de) | Arzneimittel zur Behandlung von Morbus Parkinson | |
| DE3855113T2 (de) | Verwendung von Buspiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung der Alkoholsucht | |
| DE3688038T2 (de) | Verwendung von buspiron zur herstellung von pharmazeutischen zusammensetzungen zur linderung von krankhaften angst. | |
| DE69201660T2 (de) | Verwendung von Acetyl L-Carnitin zur therapeutischen Behandlung von Coma. | |
| EP0037488B1 (de) | Pharmazeutisches Mittel zur Heilung von entzündlichen und/oder degenerativen und/oder atrophischen Schleimhauterkrankungen | |
| Shiloh et al. | Catatonia as an unusual presentation of posttraumatic stress disorder | |
| EP0618797B1 (de) | Bilobalid enthaltende pharmazeutische zubereitungen zur behandlung von spannungs- und angstzuständen | |
| DE2359128A1 (de) | Arzneimittel auf basis von lisurid und dessen physiologisch vertraeglichen salzen | |
| DE69303305T2 (de) | Mittel zur Behandlung chronischer Ermüdungserscheinungen | |
| DE69718506T2 (de) | Neue verwendung von kreatin | |
| CH662510A5 (de) | Glycyrrhizin und einen wirkstoff enthaltendes arzneimittel. | |
| DE3619426A1 (de) | Mittel zur erhoehung der widerstandskraft gegen erkaeltungskrankheiten bei patienten mit eingeschraenkter lungenfunktion | |
| EP0000774A1 (de) | Antithrombotische Arzneimittelkombination und Verfahren zu ihrer Herstellung | |
| DE3141970C2 (US08188275-20120529-C00054.png) | ||
| DE69005909T2 (de) | Mischung von Vitamin A in physiologischer Dosis und verschiedenen Wirkstoffen mit therapeutischer Wirksamkeit. | |
| DE69326331T2 (de) | Verwendung der jodwasserstoffsäure als aphrodisiakum | |
| WO1995016450A1 (de) | Verwendung von pentoxifyllin zur behandlung von multipler sklerose | |
| EP0358683A1 (de) | Pharmazeutikum | |
| DE3851669T2 (de) | Verwendung von Gepiron für Medikamente zur Milderung panischer Zustände. | |
| DE2334358A1 (de) | Pharmazeutische zubereitungen mit neuartiger wirkung | |
| EP0291751B1 (de) | Pharmazeutisches Kombinationspräparat | |
| DE60036640T2 (de) | Mittel zum stimulieren von körpergewichtzunahme, verfahren und produkt | |
| DE4112103C2 (de) | Verwendung von Essigsäure zur Regulierung der Blutzuckerwerte |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |